{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:30:06Z","timestamp":1791138606437,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/nrgastro.2014.10","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T08:16:25Z","timestamp":1391501785000},"page":"447-452","source":"Crossref","is-referenced-by-count":123,"title":["HCC therapies\u2014lessons learned"],"prefix":"10.1038","volume":"11","author":[{"given":"Marcus-Alexander","family":"W\u00f6rns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Robert","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"BFnrgastro201410_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal, A.  et al. Global cancer statistics. CA Cancer J. Clin. 61, 69\u201390 (2011).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrgastro201410_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000218351","volume":"27","author":"MA Worns","year":"2009","unstructured":"Worns, M. A., Weinmann, A., Schuchmann, M. & Galle, P. R. Systemic therapies in hepatocellular carcinoma. Dig. Dis. 27, 175\u2013188 (2009).","journal-title":"Dig. Dis."},{"key":"BFnrgastro201410_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M.  et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201410_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L.  et al. Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro201410_CR5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020\u20131022 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro201410_CR6","doi-asserted-by":"crossref","unstructured":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908\u2013943 (2012).","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"BFnrgastro201410_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/13543781003767418","volume":"19","author":"MA Worns","year":"2010","unstructured":"Worns, M. A. & Galle, P. R. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin. Investig. Drugs 19, 615\u2013629 (2010).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrgastro201410_CR8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M.  et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698\u2013711 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrgastro201410_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000347202","volume":"31","author":"MA Worns","year":"2013","unstructured":"Worns, M. A. Systemic therapy and synergies by combination. Dig. Dis. 31, 104\u2013111 (2013).","journal-title":"Dig. Dis."},{"key":"BFnrgastro201410_CR10","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng, A. L.  et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067\u20134075 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 34","key":"BFnrgastro201410_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1200\/jco.2013.31.4_suppl.249","volume":"30","author":"C Cainap","year":"2013","unstructured":"Cainap, C.  et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 30 (Suppl. 34), 249 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro201410_CR12","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson, P. J.  et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517\u20133524 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro201410_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52\u201360 (2010).","journal-title":"Semin. Liver Dis."},{"issue":"Suppl.","key":"BFnrgastro201410_CR14","first-page":"2","volume":"48","author":"AX Zhu","year":"2012","unstructured":"Zhu, A. X.  et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. Eur. J. Cancer 48 (Suppl.) 2 (2012).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro201410_CR15","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","volume":"31","author":"S Qin","year":"2013","unstructured":"Qin, S.  et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501\u20133508 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro201410_CR16","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet, J. M.  et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509\u20133516 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro201410_CR17","unstructured":"Novartis study of Afinitor\u00ae in advanced liver cancer does not meet primary endpoint of overall survival. Novartis \n                    [online]\n                    \n                  , (2013)."},{"issue":"Suppl. 3","key":"BFnrgastro201410_CR18","doi-asserted-by":"publisher","first-page":"S302","DOI":"10.1016\/S1590-8658(10)60521-X","volume":"42","author":"MA Worns","year":"2010","unstructured":"Worns, M. A. & Galle, P. R. Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 42 (Suppl. 3), S302\u2013S309 (2010).","journal-title":"Dig. Liver Dis."},{"key":"BFnrgastro201410_CR19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-12-0151","volume":"18","author":"A Villanueva","year":"2012","unstructured":"Villanueva, A. & Llovet, J. M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 18, 1824\u20131826 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro201410_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.03.025","volume":"59","author":"A Villanueva","year":"2013","unstructured":"Villanueva, A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. J. Hepatol. 59, 392\u2013395 (2013).","journal-title":"J. Hepatol."},{"key":"BFnrgastro201410_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1200\/EdBook_AM.2013.33.e137","volume":"2013","author":"RK Kelley","year":"2013","unstructured":"Kelley, R. K. & Venook, A. P. Novel therapeutics in hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2013, 137\u2013142 (2013).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"BFnrgastro201410_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329\u2013338 (1999).","journal-title":"Semin. Liver Dis."},{"key":"BFnrgastro201410_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245\u20131255 (2012).","journal-title":"Lancet"},{"key":"BFnrgastro201410_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1055\/s-2006-960171","volume":"27","author":"A Villanueva","year":"2007","unstructured":"Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. & Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55\u201376 (2007).","journal-title":"Semin. Liver Dis."},{"key":"BFnrgastro201410_CR25","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","volume":"68","author":"IB Weinstein","year":"2008","unstructured":"Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077\u20133080 (2008).","journal-title":"Cancer Res."},{"key":"BFnrgastro201410_CR26","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw, A. T.  et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385\u20132394 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201410_CR27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B.  et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro201410_CR28","first-page":"383","volume":"1","author":"JU Marquardt","year":"2012","unstructured":"Marquardt, J. U. & Andersen, J. B. Next-generation sequencing: application in liver cancer\u2014past, present and future? Biology (Basel) 1, 383\u2013394 (2012).","journal-title":"Biology (Basel)"},{"key":"BFnrgastro201410_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jhep.2011.03.004","volume":"55","author":"P Schirmacher","year":"2011","unstructured":"Schirmacher, P.  et al. Fighting the bushfire in HCC trials. J. Hepatol. 55, 276\u2013277 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro201410_CR30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1002\/hep.26124","volume":"56","author":"A Villanueva","year":"2012","unstructured":"Villanueva, A. & Llovet, J. M. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 56, 2416\u20132419 (2012).","journal-title":"Hepatology"},{"key":"BFnrgastro201410_CR31","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-13-2030","volume":"73","author":"K Pantel","year":"2013","unstructured":"Pantel, K. & Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 73, 6384\u20136388 (2013).","journal-title":"Cancer Res."},{"key":"BFnrgastro201410_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","volume":"14","author":"A Santoro","year":"2013","unstructured":"Santoro, A.  et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55\u201363 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro201410_CR33","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR34","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1593\/neo.13812","volume":"15","author":"R Schmieder","year":"2013","unstructured":"Schmieder, R.  et al. Allosteric MEK1\/2 inhibitor refametinib (BAY 86\u20139766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161\u20131171 (2013).","journal-title":"Neoplasia"},{"key":"BFnrgastro201410_CR35","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","volume":"19","author":"AX Zhu","year":"2013","unstructured":"Zhu, A. X.  et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19, 920\u2013928 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrgastro201410_CR36","unstructured":"Catalogue of Somatic Mutations in Cancer \n                    [online]\n                    \n                  ."},{"issue":"Suppl. 2","key":"BFnrgastro201410_CR37","first-page":"2467","volume":"49","author":"E Assenat","year":"2013","unstructured":"Assenat, E.  et al. Sorafenib alone versus sorafenib combined with gemcitabine and oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final results of the randomized phase II GoNext trial (a UNICANCER\/FFCD\/PRODIGE 10 study) [abstract]. Eur. J. Cancer 49 (Suppl. 2), 2467 (2013).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro201410_CR38","unstructured":"US National Library of Medicine ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR39","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907\u20131917 (2003).","journal-title":"Lancet"},{"key":"BFnrgastro201410_CR40","unstructured":"ArQule Announces Third Quarter Fiscal 2013 Results. Arqule \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR41","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.26586","volume":"58","author":"M Reig","year":"2013","unstructured":"Reig, M.  et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second line trial design. Hepatology 58, 2023\u20132031 (2013).","journal-title":"Hepatology"},{"key":"BFnrgastro201410_CR42","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2013.49.7941","volume":"31","author":"RK Kelley","year":"2013","unstructured":"Kelley, R. K. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J. Clin. Oncol. 31, 3483\u20133486 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro201410_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2013.08.027","volume":"60","author":"YY Shao","year":"2014","unstructured":"Shao, Y. Y.  et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J. Hepatol. 60, 313\u2013318 (2014).","journal-title":"J. Hepatol."},{"key":"BFnrgastro201410_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1756283X13498540","volume":"6","author":"AR He","year":"2013","unstructured":"He, A. R. & Goldenberg, A. S. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap. Adv. Gastroenterol. 6, 447\u2013458 (2013).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"BFnrgastro201410_CR45","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR46","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR47","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro201410_CR48","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2014)."},{"key":"BFnrgastro201410_CR49","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2014)."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.10","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:50:03Z","timestamp":1684468203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2014.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFnrgastro201410"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2014.10","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}